First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors.

CBP-1008 - Coherent Biopharma

https://meetings.asco.org/abstracts-presentations/223060

Jifang Gong; Jian Zhang; Ning Li; Lin Shen; Lingying Wu; Youzhong Zhang; Yi Huang; Ying Wang; Junyan Wu; Ge Lou; Yaqing Chen; Su-xia Luo; Yi Ba; Xian Wang; Yulong Zheng; Guiling Li; Zhongsheng Tong; Robert Huang; Yan Teng; Xichun Hu

Apr 27, 2023